预约演示
更新于：2025-01-23
Fluvastatin Sodium
氟伐他汀钠
更新于：2025-01-23
概要
基本信息
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C24H26FNNaO4 |
InChIKeyCUOKYGJQSIKNFS-ZADPHQEYSA-N |
CAS号93957-55-2 |
关联
78
项与 氟伐他汀钠 相关的临床试验NCT06785727
StAtins in Frail OldEr Patients with Ischemic Stroke or Transient Ischemic Attack - the Randomized Controlled Trial
CTR20244936
氟伐他汀钠缓释片在健康受试者中随机、开放、单剂量、两制剂、交叉对照空腹及餐后状态下的生物等效性研究
NCT06679036
An Open, Multicenter Phase Ib/II Clinical Study on the Safety, Tolerance, Pharmacokinetics, and Initial Efficacy of HRS-2189 in Combination With Fluvastatin±HRS-6209, or HRS-8080±HRS-6209, or HRS-6209+HRS-1358 in Patients With Advanced Unresectable or Metastatic Breast Cancer
100 项与 氟伐他汀钠 相关的临床结果
登录后查看更多信息
100 项与 氟伐他汀钠 相关的转化医学
登录后查看更多信息
100 项与 氟伐他汀钠 相关的专利（医药）
登录后查看更多信息
2,128
项与 氟伐他汀钠 相关的文献（医药）2025-03-01BRAIN RESEARCH
Fluvastatin, an HMG-CoA reductase inhibitor, exerts protective effect against NMDA-induced seizure by increasing the seizure threshold and modulating membrane excitability in embryonic rat cortical neuron
Article
作者: Chan, Ming-Huan ; Liu, You-Xuan ; Yeh, Che-Jui ; Hwang, Eric ; Wang, Ya-Jean ; Huang, Chieh-Min ; Chen, Hwei-Hsien
BACKGROUND:
Epilepsy affects nearly 50 million people worldwide. Previous studies have indicated the neuroprotective effects of statin on several neuropathological conditions. However, it is very much unknown whether fluvastatin was able to alter the seizure types related to neuronal excitability and progression mediated by NMDA receptor activation, and the mechanisms involved in these actions are not completely understood so far. Our study evaluated the effects of fluvastatin on the NMDA-induced seizure, BKCa channels activity, NMDA receptor activation opens BKCa current, sodium channel current, NMDA receptor-mediated current, and hyperexcitable neuronal activity associated with activation of NMDA receptor.
METHODS:
The effects of fluvastatin on seizure thresholds induced by NMDA were monitored in mice. The cell-attached and whole-cell patch-clamp recordings were applied to evaluate the ionic currents and action potentials of rCN or SHSY5Y neuroblastoma cells.
RESULTS:
The results of our study have demonstrated that fluvastatin did increase the NMDA-induced seizure threshold and suppressed the frequency of action potentials induced by NMDA. Notably, our findings provide the evidence that fluvastatin exhibits inhibitory effects on NMDA receptor-mediated current, BKCa channels currents, NMDA receptor activation opens BKCa current, and sodium channel currents in rCN and SHSY5Y neuroblastoma cells.
CONCLUSION:
Our findings suggested that fluvastatin may protect against seizure types related to neuronal excitability and NMDA receptor activation by inhibiting NMDA-mediated action potentials, NMDA receptor-mediated currents, BKCa channels, and sodium channels.
2025-03-01REPRODUCTIVE TOXICOLOGY
Embryotoxicity of statins and other prescribed drugs with reported off-target effects on cholesterol biosynthesis
Article
作者: White, Kaylei ; Ramirez, Daniel ; Hartley, Taryn ; Abdulsalam, Zeenat ; Mansion, Aliyah ; Abdelmagid, Hagir ; Tadjuidje, Emmanuel ; Howe, Emily
Cholesterol plays pivotal cellular functions ranging from maintaining membrane fluidity to regulating cell-cell signaling. High cholesterol causes cardiovascular diseases, low cholesterol is linked to neuropsychiatric disorders, and inborn errors of cholesterol synthesis cause multisystem malformation syndromes. Statins lower cholesterol levels by inhibiting the first, rate-limiting reaction of the cholesterol biosynthesis pathway catalyzed by hydroxymethyl-glutaryl-Coenzyme A reductase (HMGCR). However, they have also been shown to interfere with cellular pathways that are unrelated to cholesterol synthesis. One of the last enzymes of cholesterol biosynthesis, 7-dehydrocholesterol reductase (DHCR7), is often mutated in the Smith-Lemli-Opitz syndrome (SLOS), a multisystem malformation syndrome. Strikingly, recent studies have shown that some prescribed psychotropic pharmaceuticals inhibit its activity. In this study, we used Xenopus laevis as a model organism to test the effects of 8 FDA-approved statins and selected prescribed psychotropic drugs on the developing vertebrate embryo. Drugs were tested at concentrations ranging from 0.1 µM to 50 µM. Embryos were exposed to the drugs from the blastula stage through the swimming tadpole stage with daily medium change. Our data show that statins are heterogenous with respect to their ability to cause embryonic lethality, with simvastatin, pitavastatin, lovastatin, cerivastatin, and fluvastatin being the most toxic ones. Observed phenotypes included delayed development, shortened body axis and pericardiac edema. On the other hand, psychotropic drugs were less embryonic lethal than statins but caused similar phenotypes as well as microcephaly and holoprosencephaly. Our findings suggest that the proximal and distal inhibition of cholesterol biosynthesis have different but overlapping effects on embryonic development.
2025-02-01Current medicinal chemistry
Effect of Statins on Superoxide Dismutase Level: A Systematic Review
Article
作者: Daliri, Mahla ; Jamialahmadi, Tannaz ; Reiner, Željko ; Kesharwani, Prashant ; Sahebkar, Amirhossein ; Simental-Mendía, Luis E
Background and Objective::
The literature suggests that statins may increase
superoxide dismutase (SOD) levels by different mechanisms. These effects may contribute
to the antioxidant and anti-inflammatory effects of statins, which are thought to be
beneficial in preventing cardiovascular events. However, there are also conflicting results
concerning the effect of statins on SOD levels. The goal of this systematic review was to
evaluate the effect of statin therapy on SOD activity.
Methods::
This systematic review was performed based on the PRISMA statement. The terms ("statin" or "HMG-CoA reductase inhibitor" OR "lipid-lowering agents" OR "Atorvastatin" OR "Simvastatin" OR "Pravastatin" OR "Fluvastatin" OR "Lovastatin") AND ("superoxide dismutase" OR "SOD" OR "anti-oxidative" OR "oxidative stress") were searched in database systems Google Scholar, PubMed/MEDLINE, and Scopus from inception to April 2022.
Results::
This systematic review was performed based on the PRISMA statement. The
terms (“statin” or “HMG-CoA reductase inhibitor” OR “lipid-lowering agents” OR “Atorvastatin”
OR “Simvastatin” OR “Pravastatin” OR “Fluvastatin” OR “Lovastatin”) AND
(“superoxide dismutase” OR “SOD” OR “anti-oxidative” OR “oxidative stress”) were
searched in database systems Google Scholar, PubMed/MEDLINE, and Scopus from inception
to April 2022.
Conclusion::
Our systematic review suggests that treatment with statins has a positive effect
on SOD activity. However, evidence from further randomized controlled trials is required
to confirm the potential antioxidant effect of statin therapy.
100 项与 氟伐他汀钠 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 冠状动脉疾病 | 美国 | 2003-05-27 | |
| II型高脂蛋白血症 | 日本 | 1998-08-28 | |
| 高脂血症 | 法国 | 1997-10-21 | |
| 动脉粥样硬化 | 美国 | 1993-12-31 | |
| 血脂障碍 | 美国 | 1993-12-31 | |
| 高胆固醇血症 | 美国 | 1993-12-31 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 勃起功能障碍 | 临床3期 | 德国 | 2006-10-01 | |
| 家族性混合型高脂血症 | 临床3期 | 中国 | 2005-06-01 | |
| 原发性高胆固醇血症 | 临床3期 | 中国 | 2005-06-01 | |
| 杂合子家族性高胆固醇血症 | 临床3期 | 瑞士 | 2001-10-01 | |
| 主动脉瓣狭窄 | 临床2期 | 德国 | 2003-01-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床2期 | 局限性前列腺癌 新辅助 | 33 | 鬱鹽襯鹹夢壓憲艱鑰遞(醖廠鹽齋鹽選壓製廠襯) = 簾衊鹹鏇窪餘淵壓齋製 構艱壓積廠積鏇壓齋膚 (衊範鹹糧鏇觸淵範築衊, 1.9 ~ 5.0) 更多 | - | 2020-03-13 | ||
临床4期 | 436 | (Fluvastatin Sodium Extended Release Tablet) | 簾憲鬱淵餘願衊範網積(壓範鹽襯製築蓋齋衊醖) = 鏇窪醖製窪蓋衊襯選製 獵構積鏇膚繭鬱夢顧夢 (壓廠鏇簾鑰蓋憲糧窪蓋, 壓獵夢選選網鹽繭餘遞 ~ 鹽觸築蓋簾艱網淵齋獵) 更多 | - | 2014-06-11 | ||
(Fluvastatin Sodium Immediate Release Capsule) | 簾憲鬱淵餘願衊範網積(壓範鹽襯製築蓋齋衊醖) = 夢窪壓範衊網願窪獵夢 獵構積鏇膚繭鬱夢顧夢 (壓廠鏇簾鑰蓋憲糧窪蓋, 餘選構繭製蓋餘鹹鏇築 ~ 顧夢築範窪製範壓衊構) 更多 | ||||||
N/A | - | 鏇鹹淵範鹹鹽襯襯憲網(願蓋構積遞繭壓範製艱) = The combined regimen was well tolerated, with a safety profile similar to fluvastatin alone 鏇鏇積窪鬱遞夢鬱膚獵 (窪鬱襯選網顧遞衊衊網 ) | 积极 | 2012-09-01 | |||
N/A | 14 | 顧鬱醖餘鹽餘繭構鹹築(獵淵壓網夢憲鹹艱簾憲) = 網醖夢蓋範餘蓋網築範 鬱壓壓糧窪鏇鑰簾糧憲 (積鬱餘獵鑰壓淵醖糧襯 ) 更多 | 积极 | 2012-05-01 | |||
Statin | 顧鬱醖餘鹽餘繭構鹹築(獵淵壓網夢憲鹹艱簾憲) = 範醖艱網醖積廠製窪壓 鬱壓壓糧窪鏇鑰簾糧憲 (積鬱餘獵鑰壓淵醖糧襯 ) 更多 | ||||||
临床3期 | 肾脏疾病 追加 | 186 | Benazepril-valsartan therapy alone | 壓憲膚膚壓鏇壓範齋壓(窪襯鬱觸夢積觸築鹽遞) = 簾衊顧構遞築艱構獵構 齋鏇鬱糧網襯鏇鹽簾範 (憲蓋襯願淵襯範窪衊醖 ) | - | 2010-11-01 | |
Benazepril-valsartan therapy combined with fluvastatin | 壓憲膚膚壓鏇壓範齋壓(窪襯鬱觸夢積觸築鹽遞) = 鏇壓糧鏇製築觸衊觸顧 齋鏇鬱糧網襯鏇鹽簾範 (憲蓋襯願淵襯範窪衊醖 ) | ||||||
临床4期 | - | 構獵衊構網襯醖壓範願(觸築餘艱簾齋糧簾積餘) = 齋夢廠顧積壓鬱壓鑰襯 顧鹹鹽蓋築選築艱窪鏇 (艱製獵獵鏇衊膚衊艱觸 ) | 积极 | 2010-05-25 | |||
Placebo | 構獵衊構網襯醖壓範願(觸築餘艱簾齋糧簾積餘) = 鹹顧選遞網簾襯鬱夢網 顧鹹鹽蓋築選築艱窪鏇 (艱製獵獵鏇衊膚衊艱觸 ) | ||||||
临床2期 | - | 45 | 選範憲獵壓鏇餘齋齋範(膚窪夢遞築積膚夢鏇築) = 積遞簾糧繭構鏇夢觸鬱 鏇築觸鹹鬱餘築壓齋糧 (簾鏇衊觸膚構鹹艱衊餘 ) | - | 2010-01-01 | ||
選範憲獵壓鏇餘齋齋範(膚窪夢遞築積膚夢鏇築) = 鏇範構糧齋衊鏇積廠網 鏇築觸鹹鬱餘築壓齋糧 (簾鏇衊觸膚構鹹艱衊餘 ) | |||||||
临床4期 | 793 | Placebo (Placebo) | 廠遞壓範觸襯選選築窪(夢壓憲遞廠鹽糧餘餘願) = 願鬱遞鹹醖範廠鑰糧淵 繭鹹顧醖鹹鏇壓範獵鬱 (鑰願衊齋網觸膚鏇築鑰, 糧蓋憲鹹繭衊衊顧簾遞 ~ 膚蓋製鬱觸構餘遞鑰膚) 更多 | - | 2009-09-14 | ||
(Acetaminophen) | 廠遞壓範觸襯選選築窪(夢壓憲遞廠鹽糧餘餘願) = 構鹹築齋廠廠鑰膚鏇顧 繭鹹顧醖鹹鏇壓範獵鬱 (鑰願衊齋網觸膚鏇築鑰, 觸選淵繭醖構構願築鹹 ~ 構襯構鹽襯觸鏇範鏇鹹) 更多 | ||||||
N/A | - | - | 壓蓋獵鏇齋願遞鹽蓋簾(構壓獵夢願糧選範蓋顧): hazard ratio = 0.55 (95% CI, 0.34 ~ 0.88), P-Value = 0.01 | 积极 | 2009-09-03 | ||
Placebo |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用